Related Experiment Video
Updated: Jan 8, 2026
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Fatal interstitial lung disease associated with rituximab in diffuse large B-cell lymphoma: A case report and
1Department of Respirology, Yidu Central Hospital of Weifang, Qingzhou, Shandong Province, China.
Rationale:
Rituximab-associated interstitial lung disease (ILD) may initially be asymptomatic, and serial monitoring of serum tumor necrosis factor-alpha levels may facilitate timely diagnostic intervention with pulmonary computed tomography.
Patient Concerns:
A 73-year-old patient with diffuse large B-cell lymphoma (DLBCL) developed ILD during treatment with a rituximab-containing regimen.
Diagnoses:
Rituximab-associated interstitial disease was made.
Interventions:
The patient was treated with corticosteroids, intravenous immunoglobulin, and antifibrotic therapy.
Outcomes:
The ILD progressed, and the patient ultimately succumbed to type I respiratory failure.
Lessons:
Clinicians should remain vigilant for rituximab-associated ILD, which, although uncommon, can progress rapidly and result in poor outcomes.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018